{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:08:55Z","timestamp":1761743335539},"reference-count":151,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.parkreldis.2010.02.015","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T04:42:05Z","timestamp":1269492125000},"page":"307-315","source":"Crossref","is-referenced-by-count":28,"title":["Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies"],"prefix":"10.1016","volume":"16","author":[{"given":"Krisztina K.","family":"Johansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda R.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid B.","family":"Sando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan O.","family":"Aasly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2010.02.015_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00685366","article-title":"Presenile dementia with Alzheimer-, Pick- and Lewy-body changes","volume":"36","author":"Kosaka","year":"1976","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-2006-9S347","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop","volume":"9","author":"McKeith","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11065-008-9055-0","article-title":"Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for \u201cmild cognitive impairment\u201d and biomarkers","volume":"18","author":"Troster","year":"2008","journal-title":"Neuropsychol Rev"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jnnp.51.2.244","article-title":"The effect of age of disease onset on neuropsychological performance in Parkinson's disease","volume":"51","author":"Hietanen","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","article-title":"A\u00a0population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender","volume":"49","author":"Mayeux","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/978-1-4757-0145-6_25","article-title":"The epidemiology of dementia in patients with Parkinson's disease","volume":"295","author":"Marder","year":"1991","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1212\/WNL.37.2.226","article-title":"A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease","volume":"37","author":"Rajput","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euroneuro.2005.04.007","article-title":"Prevalence and incidence of Parkinson's disease in Europe","volume":"15","author":"von Campenhausen","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/brain\/awh067","article-title":"The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study","volume":"127","author":"Foltynie","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mds.20513","article-title":"Clinical characteristics in early Parkinson's disease in a central California population-based study","volume":"20","author":"Kang","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0447.2007.01006.x","article-title":"Prevalence of dementia in a southern European population in two different time periods: the ZARADEMP project","volume":"116","author":"Lobo","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000109998","article-title":"Prevalence of dementia in the United States: the aging, demographics, and memory study","volume":"29","author":"Plassman","year":"2007","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ageing\/afi190","article-title":"A systematic review of prevalence and incidence studies of dementia with Lewy bodies","volume":"34","author":"Zaccai","year":"2005","journal-title":"Age Ageing"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.58.2.209","article-title":"Incidence of AD may decline in the early 90s for men, later for women: the Cache County study","volume":"58","author":"Miech","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","article-title":"A systematic review of prevalence studies of dementia in Parkinson's disease","volume":"20","author":"Aarsland","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","article-title":"Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study","volume":"72","author":"Aarsland","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0967-5868(96)90028-4","article-title":"A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia","volume":"3","author":"Reid","year":"1996","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-510X(03)00220-X","article-title":"Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson's disease with dementia","volume":"216","author":"Horimoto","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1600-0404.1997.tb00299.x","article-title":"The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies","volume":"96","author":"Ballard","year":"1997","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jnnp.2005.081711","article-title":"Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies","volume":"77","author":"Burn","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/mds.10455","article-title":"Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study","volume":"18","author":"Burn","year":"2003","journal-title":"Mov Disord"},{"issue":"Suppl. 5","key":"10.1016\/j.parkreldis.2010.02.015_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00415-008-5007-0","article-title":"Lewy body dementia and Parkinson's disease with dementia","volume":"255","author":"Dodel","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/jnnp.62.3.243","article-title":"Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases","volume":"62","author":"Gnanalingham","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1176\/appi.neuropsych.13.3.374","article-title":"Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease","volume":"13","author":"Aarsland","year":"2001","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib28","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/WNL.54.9.1774","article-title":"Predictors of progression in patients with AD and Lewy bodies","volume":"54","author":"Lopez","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib29","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","article-title":"Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies","volume":"60","author":"Merdes","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib31","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","article-title":"Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/mds.20897","article-title":"Changes in motor subtype and risk for incident dementia in Parkinson's disease","volume":"21","author":"Alves","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000109756","article-title":"Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease","volume":"16","author":"Goldmann Gross","year":"2008","journal-title":"Neurosignals"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/0891988704267470","article-title":"Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?","volume":"17","author":"Aarsland","year":"2004","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib35","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","article-title":"Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease","volume":"73","author":"Hoops","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.parkreldis.2008.05.006","article-title":"Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores","volume":"15","author":"Mamikonyan","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00415-008-0720-2","article-title":"Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German study on epidemiology of Parkinson's disease with dementia (GEPAD)","volume":"255","author":"Riedel","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib38","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181bacf9e","article-title":"Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies","volume":"73","author":"Nelson","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib39","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"\u03b1-Synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10846","article-title":"Comparison of kindreds with parkinsonism and \u03b1-synuclein genomic multiplications","volume":"55","author":"Farrer","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding \u03b1-synuclein in Parkinson's disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib42","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.parkreldis.2009.09.010","article-title":"Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease","volume":"15","author":"Ahlskog","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ana.20456","article-title":"Clinical features of LRRK2-associated Parkinson's disease in central Norway","volume":"57","author":"Aasly","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib45","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1212\/01.WNL.0000125015.06989.DB","article-title":"Autosomal dominant parkinsonism associated with variable synuclein and tau pathology","volume":"62","author":"Wszolek","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib47","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.20928","article-title":"LRRK2 protein is a component of Lewy bodies","volume":"60","author":"Zhu","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000113708","article-title":"Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies","volume":"5","author":"Perry","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archneurol.2009.54","article-title":"Association of glucocerebrosidase mutations with dementia with lewy bodies","volume":"66","author":"Clark","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib50","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/mds.21892","article-title":"Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy","volume":"23","author":"De Marco","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib51","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.parkreldis.2008.08.004","article-title":"Glucosidase-beta variations and Lewy body disorders","volume":"15","author":"Farrer","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib52","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib53","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/01.jnen.0000199572.96472.1c","article-title":"Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology","volume":"65","author":"Ghebremedhin","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archneur.63.2.189","article-title":"Apolipoprotein E and dementia in Parkinson disease: a meta-analysis","volume":"63","author":"Huang","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2006.12.008","article-title":"Phenotypic associations of tau and ApoE in Parkinson's disease","volume":"414","author":"Papapetropoulos","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archneur.64.2.261","article-title":"Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia","volume":"64","author":"Jasinska-Myga","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib58","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/01.JGP.0000225088.29353.08","article-title":"APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk","volume":"14","author":"Borroni","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000066022","article-title":"Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies","volume":"14","author":"Singleton","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib60","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/jnnp.74.8.1148","article-title":"Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects","volume":"74","author":"Engelborghs","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib61","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/mds.22357","article-title":"BuChE-K and APOE\u025b4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline","volume":"24","author":"Lane","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mds.10295","article-title":"Prevalence of amyloid- \u03b2 deposition in the cerebral cortex in Parkinson's disease","volume":"18","author":"Mastaglia","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib64","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000197890","article-title":"Significance of brain lesions in Parkinson disease dementia and Lewy body dementia","volume":"24","author":"Jellinger","year":"2009","journal-title":"Front Neurol Neurosci"},{"issue":"Suppl. 3","key":"10.1016\/j.parkreldis.2010.02.015_bib65","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S1353-8020(08)70005-1","article-title":"Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology","volume":"13","author":"Tsuboi","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl. 1","key":"10.1016\/j.parkreldis.2010.02.015_bib66","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.parkreldis.2004.10.014","article-title":"Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?","volume":"11","author":"Tsuboi","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00401-006-0088-2","article-title":"Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?","volume":"112","author":"Jellinger","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neulet.2009.05.083","article-title":"Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies","volume":"461","author":"Kalaitzakis","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib69","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.parkreldis.2008.05.007","article-title":"Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease","volume":"15","author":"Kalaitzakis","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib70","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib71","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00401-007-0261-2","article-title":"Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases","volume":"114","author":"Nakashima-Yasuda","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib72","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2008.04.033","article-title":"Brain magnetic resonance imaging (MRI) in parkinsonian disorders","volume":"15","author":"Sitburana","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00702-002-0785-5","article-title":"Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD","volume":"110","author":"Yekhlef","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib74","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1212\/WNL.52.6.1153","article-title":"Medial temporal lobe atrophy on MRI in dementia with Lewy bodies","volume":"52","author":"Barber","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib75","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/mds.22488","article-title":"Correlations between gray matter reductions and cognitive deficits in dementia with Lewy Bodies and Parkinson's disease with dementia","volume":"24","author":"Sanchez-Castaneda","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib76","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00702-005-0401-6","article-title":"Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome","volume":"113","author":"Hesse","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.56.5.529","article-title":"Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA","volume":"56","author":"Fahn","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib79","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/jnnp.2009.172825","article-title":"Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs)","volume":"80","author":"Silveira-Moriyama","year":"2009","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-3-211-45295-0_63","article-title":"A new look at levodopa based on the ELLDOPA study","author":"Fahn","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1192\/bjp.bp.108.052050","article-title":"Diagnostic accuracy of123I-FP-CIT SPECT in possible dementia with Lewy bodies","volume":"194","author":"O'Brien","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib82","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-510X(93)90040-6","article-title":"Positron emission tomographic (PET) studies in dementia","volume":"114","author":"Goto","year":"1993","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib84","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JGP.0b013e3181961a6f","article-title":"Fluoro-deoxy-glucose positron emission tomography correlates of impaired activities of daily living in dementia with Lewy bodies: implications for cognitive reserve","volume":"17","author":"Perneczky","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(99)00011-8","article-title":"Parieto-occipital glucose hypometabolism in Parkinson's disease with autonomic failure","volume":"163","author":"Arahata","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib86","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1468-1331.2007.01977.x","article-title":"A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies","volume":"14","author":"Yong","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib87","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s00259-002-0919-x","article-title":"Value of 99mTc-ECD SPET for the diagnosis of dementia with Lewy bodies","volume":"29","author":"Pasquier","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00259-002-0778-5","article-title":"A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping","volume":"29","author":"Colloby","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib89","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/01.mnm.0000243370.18883.62","article-title":"Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment","volume":"27","author":"Derejko","year":"2006","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib90","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jnnp.2006.100073","article-title":"Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia","volume":"78","author":"Bohnen","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib91","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.0b013e3181ab2b58","article-title":"Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET","volume":"73","author":"Shimada","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib92","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.nbd.2008.12.008","article-title":"Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics","volume":"34","author":"Maetzler","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib93","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib94","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.parkreldis.2008.10.001","article-title":"Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease","volume":"15","author":"Lunardi","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0404.1995.tb01023.x","article-title":"CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease","volume":"92","author":"Eldrup","year":"1995","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib96","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","article-title":"The plasma \u03b1-synuclein levels in patients with Parkinson's disease and multiple system atrophy","volume":"113","author":"Lee","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib97","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","article-title":"Plasma \u03b1-synuclein is decreased in subjects with Parkinson's disease","volume":"204","author":"Li","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib98","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","article-title":"\u03b1-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma","volume":"17","author":"El-Agnaf","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib99","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of \u03b1-synuclein protein in human plasma as a potential biomarker for Parkinson's disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3940(00)01153-8","article-title":"Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects","volume":"287","author":"Borghi","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib101","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","article-title":"Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease","volume":"349","author":"Tokuda","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib102","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib103","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","article-title":"Cerebrospinal fluid \u03b1-synuclein in neurodegenerative disorders-a marker of synapse loss?","volume":"450","author":"Ohrfelt","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S1041610209991049","article-title":"\u03b1-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies","volume":"22","author":"Ballard","year":"2010","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A \u03b242 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib106","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","article-title":"CSF levels of tau, \u03b2-amyloid1\u201342 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging","volume":"107","author":"Sj\u00f6gren","year":"2000","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib107","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-003-0075-x","article-title":"Immunoreactivities of amyloid beta peptide (1-42) and total \u03c4 protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus","volume":"111","author":"Lins","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib108","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mds.10321","article-title":"Cerebrospinal fluid A \u03b242 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy","volume":"18","author":"Holmberg","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib109","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1212\/WNL.54.9.1875","article-title":"Decreased CSF amyloid \u03b242 and normal tau levels in dementia with Lewy bodies","volume":"54","author":"Kanemaru","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000094871","article-title":"Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia","volume":"22","author":"Mollenhauer","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib111","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","article-title":"Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies","volume":"64","author":"Parnetti","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib112","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/brain\/awl063","article-title":"CSF amyloid- \u03b2-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia","volume":"129","author":"Bibl","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib113","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000083178","article-title":"Tau protein, A \u03b242 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"19","author":"Mollenhauer","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib114","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archneur.60.9.1218","article-title":"Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease","volume":"60","author":"G\u00f3mez-Tortosa","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib115","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1212\/WNL.56.4.576","article-title":"Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies","volume":"56","author":"Tschampa","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib116","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/bbrc.1997.6908","article-title":"Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology","volume":"236","author":"Arai","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib117","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymeth.2007.06.012","article-title":"Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases","volume":"44","author":"Otto","year":"2008","journal-title":"Methods"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib118","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1309\/W01Y0B808EMEH12L","article-title":"CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases","volume":"129","author":"Zhang","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib119","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","article-title":"Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders","volume":"9","author":"Abdi","year":"2006","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1750-3639.2007.00048.x","article-title":"Proteomic identification of novel proteins in cortical lewy bodies","volume":"17","author":"Leverenz","year":"2007","journal-title":"Brain Pathol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib121","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/pmic.200400848","article-title":"Proteome analysis of human substantia nigra in Parkinson's disease","volume":"4","author":"Basso","year":"2004","journal-title":"Proteomics"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.mad.2005.09.021","article-title":"Proteome studies of CSF in AD patients","volume":"127","author":"Davidsson","year":"2006","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib123","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.21038","article-title":"Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease","volume":"61","author":"Finehout","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib124","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1074\/mcp.M500382-MCP200","article-title":"Proteomic identification of a stress protein, mortalin\/mthsp70\/GRP75: relevance to Parkinson disease","volume":"5","author":"Jin","year":"2006","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","article-title":"Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease","volume":"118","author":"Puchades","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib126","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-5956-6-8","article-title":"Proteome analysis of human substantia nigra in Parkinson's disease","volume":"6","author":"Werner","year":"2008","journal-title":"Proteome Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib127","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/brain\/awm304","article-title":"Metabolomic profiling to develop blood biomarkers for Parkinson's disease","volume":"131","author":"Bogdanov","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007551","article-title":"Metabolomic profiling in LRRK2-related Parkinson's disease","volume":"4","author":"Johansen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.pharmtox.41.1.347","article-title":"Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies","volume":"41","author":"Lesko","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib131","first-page":"109","article-title":"Molecular and biochemical markers of Alzheimer's disease\u201c","volume":"19","author":"Consensus report of the Working Group","year":"1998","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib132","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.neuroimage.2009.05.017","article-title":"MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study","volume":"47","author":"Menke","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib133","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1212\/01.wnl.0000340982.01727.6e","article-title":"High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease","volume":"72","author":"Vaillancourt","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib134","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JAD-2009-1177","article-title":"Cerebrospinal fluid biomarkers for Alzheimer's disease","volume":"18","author":"Blennow","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib135","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","article-title":"Amyloid- \u03b2 dynamics are regulated by orexin and the sleep\u2013wake cycle","volume":"326","author":"Kang","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib136","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1017\/S1355617702813248","article-title":"What is cognitive reserve? Theory and research application of the reserve concept","volume":"8","author":"Stern","year":"2002","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib137","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/mds.20652","article-title":"Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging","volume":"20","author":"Burton","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib138","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1212\/WNL.56.10.1386","article-title":"Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia","volume":"56","author":"O'Brien","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib139","first-page":"320","article-title":"Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease","volume":"24","author":"Donnemiller","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuroimage.2006.07.026","article-title":"In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia","volume":"33","author":"Colloby","year":"2006","journal-title":"Neuroimage"},{"issue":"Suppl. 2","key":"10.1016\/j.parkreldis.2010.02.015_bib141","doi-asserted-by":"crossref","first-page":"S742","DOI":"10.1002\/mds.22581","article-title":"Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography","volume":"24","author":"Brooks","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib142","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jns.2007.08.018","article-title":"Serum heart-fatty acid binding protein levels in patients with Lewy body disease","volume":"266","author":"Wada-Isoe","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib143","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000105157","article-title":"Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies","volume":"4","author":"Mollenhauer","year":"2007","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib144","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2004.07.061","article-title":"Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases","volume":"370","author":"Steinacker","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2006.08.004","article-title":"CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration","volume":"250","author":"Yasui","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib146","first-page":"139","article-title":"Parkinsonism with excessive daytime sleepiness\u2013a narcolepsy-like disorder?","volume":"252","author":"Baumann","year":"2005","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib147","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000079749","article-title":"Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness","volume":"52","author":"Baumann","year":"2004","journal-title":"Eur Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib148","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2007.08.010","article-title":"Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease","volume":"425","author":"Waragai","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib149","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1212\/01.wnl.0000271077.82508.a0","article-title":"Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies","volume":"69","author":"Nielsen","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-510X(97)00069-5","article-title":"Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease","volume":"150","author":"Molina","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2010.02.015_bib151","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0022-510X(95)00146-S","article-title":"Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease","volume":"133","author":"Chia","year":"1995","journal-title":"J Neurol Sci"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802010000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802010000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T12:05:17Z","timestamp":1558958717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802010000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":151,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1353802010000532"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2010.02.015","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}